| NCT02312245 | II | Recurrent ovarian cancer | Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers | AZ, FL, MN | View Drugs | |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02873962 | II | Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor) | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01851369 | II | Granulosa cell ovarian cancer | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiation therapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | CA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03348631 | II | Recurrent or persistent endometrioid/clear cell ovarian cancer with ARID1A mutations | A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma | AK, AZ, AR, CA, CO, CT, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MA, MI, MN, MO, MT, NE, NV, NJ, NY, ND, OH, OK, OR, PA, RI, SC, SD, TX, UT, VA, WA, WI, WY | View Drugs | |
Tazemetostat | histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438, Tazverik | EZH2 histone methyltransferase inhibitor | Approved in Other Cancers |
|
|
| NCT03355976 | II | Recurrent clear cell ovarian cancer | BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | IL, RI | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03428802 | II | Advanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ, NY | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03462342 | II | Platinum sensitive high grade serous ovarian cancer (cohort A), or BRCA MUT or HRD+ platinum sensitive high grade serous ovarian cancer w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII) | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer | MD, MA, PA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | CA, MD, MI, MO, NY | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03579316 | II | Platinum sensitive BRCA MUT or HRD+ ovarian cancer that must have benefited from and then progressed on prior PARP inhibitor therapy | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | MA, TX | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03651271 | II | Recurrent ovarian cancer with dMMR, high MSI or high TMB | An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer | CA, NY, TX | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A (except clear cell) or ATM alterations | Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03693014 | II | Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | CT, NJ, NY, PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03673124 | II | Recurrent low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | CA, FL, GA, IL, IN, MI, MN, NH, NJ, NM, OH, OK, PA, RI, TX | View Drugs | View Results |
Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03909152 | II | Recurrent PR+ low grade serous or granulosa cell ovarian cancer | Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor), Alone or In Combination With Anastrozole in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer | NJ, NY | View Drugs | View Results |
Anastrozole | Arimidex | Aromatase inhibitor | | Onapristone ER | ONA-XR, extended-release onapristone | PR antagonist that blocks PR activation and the associated expression of PR-responsive genes | Clinical Trials |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02710253 | II | Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03449108 | II | Recurrent high grade ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | View Results |
Aldesleukin | | IL-2 receptor agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | LN-145-S1 | Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy | Immune response against tumor-associated antigens | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | GDC-0084, PI3K inhibitor GDC-0084, RG7666 | PI3K/mTOR inhibitor | Clinical Trials |
|
|
| NCT04083976 | II | Advanced solid tumors with FGFR mutations or fusions | A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations | AZ, CO, FL, GA, HI, ME, MA, NJ, NY, NC, OH, PA, TN, TX, WA, WI | View Drugs | View Results |
Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04383210 | II | Advanced solid tumors with a NRG1 gene fusion | CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors | AL, AZ, CA, CO, DE, DC, FL, GA, HI, IL, MA, MI, MN, MO, NE, NY, NC, OH, OR, PA, TN, TX, UT, VA, WA, WI | View Drugs | |
Seribantumab | SAR256212, MM-121 | ERBB3 antagonist | Clinical Trials |
|
|
| NCT04393454 | II | Advanced solid tumors with dMMR that must have had prior immunotherapy | Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | NY | View Drugs | View Results |
Sirolimus | Rapamycin, Rapamune | mTOR inhibitor | Approved in Other Indications |
|
|
| NCT04449549 | II | Recurrent rare tumors | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04482309 | II | Advanced HER2+ solid tumors | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | CA, IL, IN, MA, NJ, NY, NC, TN, TX, VA, WA | View Drugs | |
Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT04534283 | II | Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1 | A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1. | IN | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Temuterkib | LY3214996 | ERK inhibitor | Clinical Trials |
|
|
| NCT04550494 | II | Advanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; gBRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | MD | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04564027 | II | Advanced solid tumors with ATM mutations | A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) | CA, FL, IN, LA, MD, MI, MN, NV, NY, PA, SC | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | MI, UT | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2 AMP, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | AL, AZ, CA, DE, FL, GA, ID, IL, ME, MD, MI, MN, MO, MT, NV, NJ, NM, NY, OH, OR, PA, SC, TN, TX, VA, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Idasanutlin | RO5503781, RG7388, MDM2 antagonist RO5503781 | MDM2 antagonist | | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04625270 | II | Recurrent low grade serous ovarian cancer with KRAS MUT | A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | AZ, CA, CT, FL, IL, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA | View Drugs | View Results |
Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials | VS-6766 | CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766 | RAF and MEK inhibitor | Clinical Trials |
|
|
| NCT04632992 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, RET, ROS1 or with high TMB or high MSI | MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | AL, AK, AZ, AR, CA, CT, FL, ID, LA, MD, MI, MO, MT, NE, NJ, NY, NC, OH, OR, TN, TX, VA, WA | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | Pralsetinib | BLU-667 | RET-kinase inhibitor | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable activation of DNAM-1 signaling in NK and CD8 T cells | Clinical Trials | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04729348 | II | Advanced solid tumors with leptomeningeal metastases | Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases | MA | View Drugs | |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04739618 | II | Advanced solid tumors - intratumoral injection | A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer | AZ | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Thermotherapy | | | Clinical Trials |
|
|
| NCT04771520 | II | Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I) | Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors | TX | View Drugs | |
Avapritinib | | PDGFRa and c-Kit inhibitor | Approved in Other Cancers |
|
|
| NCT02896335 | II | Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A | A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway | MA | View Drugs | View Results |
Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04189445 | II | Advanced solid tumors with FGFR1-4 alterations | A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS | AZ, CA, DC, IL, MD, MA, MI, OK, PA, TX | View Drugs | View Results |
Futibatinib | FGFR inhibitor TAS-120, TAS-120 | FGFR1-4 inhibitor | Clinical Trials |
|
|
| NCT04919629 | II | Recurrent ovarian cancer with symptomatic ascites or pleural effusion | Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion | NY | View Drugs | |
APL-2 | C3-targeted complement inhibitor APL-2 | Blocks the cleavage of C3 | Approved in Other Indications | Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04957615 | II | Advanced solid tumors with ARID1A mutations | A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors | TX | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05041257 | II | Platinum sensitive FRalpha+ high grade serous ovarian cancer with ≥2 prior platinum regimens, not eligible for further platinum therapy; BRCA MUT patients must have had prior PARP inhibitor therapy | A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO) | AZ, CO, FL, LA, ME, NJ, OH, OR, RI, TN, TX, VA, WA | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT05064280 | II | Advanced solid tumors with brain metastases | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | TX | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05071937 | II | Platinum sensitive ovarian cancer that must have progressed on or after prior PARP inhibitor therapy (≤4 cytotoxic chemotherapy or DNA-damage response agents containing regimens) | Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05082025 | II | Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Fulvestrant | Faslodex, ICI 182,780, ZD9238 | ER antagonist (SERD) | Approved in Other Cancers |
|
|
| NCT05097599 | II | Advanced solid tumors with ALK or ROS1 fusions, BRAF V600X, gBRCA1/2, gPALB2 alterations, or HER2+ or Nectin-4+ | Strata PATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors | OH | View Drugs | |
Binimetinib | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi | MEK inhibitor | Approved in Other Cancers | Encorafenib | Raf Kinase Inhibitor LGX818, LGX818 | RAF inhibitor | Approved in Other Cancers | Enfortumab Vedotin | | ADC: anti-Nectin-4 + microtubule destabilizer (MMAE) | Approved in Other Cancers | Lorlatinib | PF-06463922 | ALK and ROS1 kinase inhibitor | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT05113368 | II | Recurrect low grade serous ovarian cancer | Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial | PA | View Drugs | |
Fulvestrant | Faslodex, ICI 182,780, ZD9238 | ER antagonist (SERD) | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers |
|
|
| NCT05128825 | II | Advanced solid tumors with DDR pathway alterations | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN-c3 IN SUBJECTS WITH MALIGNANT TUMORS HARBORING DNA DAMAGE PATHWAY BIOMARKERS (ZN-c3-005/ GOG-3066/DENALI) | CO, MD, PA, TX, VA | View Drugs | View Results |
ZN-c3 | | WEE1 inhibitor | Clinical Trials |
|
|
| NCT05185947 | II | Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV) | Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05199584 | II | Advanced solid tumors with loss of function PTCH1 mutations | A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | CA, FL, NY, OH, PA, TN, TX | View Drugs | |
Taladegib | LY2940680, ENV-101 | Smoothened antagonist | Clinical Trials |
|
|
| NCT04992013 | II | Ovarian cancer with brain metastasis and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS) | Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS | MA | View Drugs | View Results |
|
|
| NCT05231122 | II | Recurrent serous, endometrioid or clear cell ovarian cancer | Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer | NY, TX | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | CDX-1140 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05286801 | II | Advanced solid tumors with loss of SMARCB1 or SMARCA1 | A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Contact research study staff | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable activation of DNAM-1 signaling in NK and CD8 T cells | Clinical Trials |
|
|
| NCT05296512 | II | Recurrent or persistent clear cell ovarian cancer | A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary | MA | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05335993 | II | Platinum sensitive high grade serous ovarian cancer with CA125-associated recurrence | Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer | NC, OK, VA | View Drugs | |
Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer | Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | Clinical Trials |
|
|
| NCT04669002 | II | High grade ovarian cancer with primary platinum resistance or platinum sensitive high grade ovarian cancer that must have had prior PARP inhibitor maintenance as most recent therapy | Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance | FL, GA, NY, PA, SC, TN, VA | View Drugs | View Results |
EP0057 | IT-101, cyclodextrin-based polymer-camptothecin CRLX101, camptothecin-polymer conjugate IT-101, CRLX101, NLG207 | Topoisomerase I inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05001347 | II | Platinum resistant or refractory ovarian cancer; all histologies except high grade serous must have PD-L1 CPS ≥ 1% | A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors | AZ, CA, DE, IL, LA, MD, NY, OH, TX, VA, WA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Uliledlimab | TJD5, TJ004309 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells | Clinical Trials |
|
|
| NCT05032040 | II | Platinum resistant high grade serous or recurrent clear cell ovarian cancer (<2 prior chemotherapy regimens) | A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer | Contact research study staff | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT04332653 | Ib/IIa | Advanced solid tumors | An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors | FL, MI, MO, NC, PA, TN, TX | View Drugs | View Results |
Efineptakin alfa | NT-I7, GX-I7, Hyleukin, recombinant human IL-7-hybrid Fc NT-I7, TJ107 | IL-7R agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03586661 | Ib | Recurrent high grade serous ovarian cancer or BRCA MUT ovarian cancer that must have progressed after PARP inhibitor maintenance therapy (in expansion) | A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03725436 | Ib | Advanced solid tumors that are TP53 WT with MDM2 AMP or MDM4 AMP (in expansion) | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer | TX | View Drugs | View Results |
ALRN-6924 | MDM2/MDMX inhibitor ALRN-6924 | MDM2 and MDMX inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03872947 | Ib | Recurrent ovarian cancer | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, LA, NJ, NY, OR, TX, VA, WI | View Drugs | |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|
| NCT03842228 | Ib | Advanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA (E542, E545 or H1047), POLD1, PPP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (in expansion) | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors | CO, MA, TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04244552 | Ib | Advanced solid tumors (ATRC-101) or high grade serous platinum resistant or refractory ovarian cancer (ATRC-101+PLD) | A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies | AZ, CA, DC, FL, MA, MN, NY, NC, OK, TN | View Drugs | View Results |
ATRC-101 | | Anti-tumor immune response | Clinical Trials | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04140526 | Ia/Ib | Advanced solid tumors (in ovarian expansion) | Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001) | AZ, CA, CO, CT, DC, FL, GA, KY, MD, MA, MI, NJ, NY, OH, PA, TN, TX, UT, VA | View Drugs | View Results |
ONC-392 | | Blocks CTLA-4 inhibition of T cells | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03593226 | I/IIa | Advanced solid tumors - intratumoral injection (Phase II) | A Phase I/IIA, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours | CA, OR | View Drugs | |
AGI-134 | αGal immunotherapy | Anti-tumor immune response | |
|
|
| NCT04130516 | I/IIa | Advanced solid tumors (Phase II) | A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab | CA, CT, MA, NM, PA, TX | View Drugs | View Results |
LNS8801 | G protein-coupled estrogen receptor agonist LNS8801 | GPER agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04657068 | I/IIa | Advanced solid tumors with alterations in ATM (ART0380) or platinum resistant high grade serous ovarian cancer (ART0380+gemcitabine) (1≤ prior therapy for platinum resistant disease) (Phase II) | A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors | CO, FL, OK, PA, TN | View Drugs | View Results |
ART0380 | | ATR kinase inhibitor | Clinical Trials | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer (Phase II) | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03400332 | I/II | Advanced solid tumors (Phase II) | A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | AR, MD, NJ, NY, OK, PA, TX, UT | View Drugs | View Results |
HuMax-IL8 | MDX 018, anti-IL-8 monoclonal antibody HuMax-IL8, BMS-986253 | IL-8 antagonist | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03157128 | I/II | Advanced solid tumors with RET alterations (Phase II) | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
Selpercatinib | LOXO-292, RET kinase inhibitor LOXO-292, Retevmo | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03767348 | I/II | Advanced solid tumor with high MSI or dMMR - intratumoral injection (Phase II) | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | AZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, PA, SC, TN, UT, WA, WI | View Drugs | View Results |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | RP1 | oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03861793 | I/II | Recurrent ovarian cancer (Phase II) | A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001) | CA, DC, GA, IL, MD, MI, MN, NJ, NY, NC, OH, PA, SC, TX, UT, WI | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03907852 | I/II | Advanced mesothelin+ solid tumors (Phase II) | A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer | CA, MD, NY, PA, TN, TX | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Gavocabtagene autoleucel | autologous anti-mesothelin T-cell receptor fusion construct T cells TC-210, TC-210 TruC-T cells, TC-210 T cells | Immune response against cancer expressing mesothelin | Clinical Trials |
|
|
| NCT03746431 | I/II | Advanced solid tumors (inc ovarian expansion) | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours | CA, MA, MN, NY, PA, TX | View Drugs | |
[225Ac]-FPI-1434 | | Radioimmunotherapy: anti-IGF-1R + Actinium-225 | Clinical Trials |
|
|
| NCT03416335 | I/II | Advanced solid tumors (Phase II) | A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | NC, PA, TN, TX | View Drugs | |
DSP-0509 | toll-like receptor 7 agonist DSP-0509 | TLR7 agonist and immune cell activator | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03568656 | I/II | Advanced solid tumors with alterations in ARID1A, CREBBP, EP300, or MYC or AR overexpression | An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours. | MA, PA | View Drugs | |
CCS1477 | p300 HAT/CREB binding protein inhibitor CCS1477, p300/CBP bromodomain inhibitor CCS1477, Inobrodib | p300/CBP inhibitor | Clinical Trials |
|
|
| NCT03997968 | I/II | Recurrent ovarian cancer that must have had prior PARP inhibitor therapy (Phase II) | A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors | AZ, CA, CO, FL, MA, MI, MN, NJ, NY, OK, PA, TN, TX, WA, WI | View Drugs | View Results |
|
|
| NCT04021043 | I/II | Advanced solid tumors (Phase II) | Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies | TX | View Drugs | View Results |
BMS-986156 | | GITR (glucocorticoid-induced TNFR) agonist | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT04317105 | I/II | Advanced solid tumors with PIK3CA mutations (E542, E545, or H1047) or PTEN mutations (Phase II) | A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors | MA, TX, VA | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04084366 | I/II | Advanced Globo H+ solid tumors (Phase II) | A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors | CA, NY, TN, TX | View Drugs | |
OBI-999 | anti-globo H/MMAE antibody-drug conjugate OBI 999 | ADC: anti-Globo H + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT03093116 | I/II | Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II) | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TX, VA, WA, WI | View Drugs | View Results |
Repotrectinib | ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005 | ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor | Clinical Trials |
|
|
| NCT03175224 | I/II | Advanced solid tumors with MET AMP or MET gene fusions (Phase II) | Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | AZ, CA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, UT, WV, WI | View Drugs | View Results |
Bozitinib | APL-101, CBT-101, Vebreltinib | c-Met kinase inhibitor | Clinical Trials |
|
|
| NCT04590326 | I/II | Recurrent ovarian cancer | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3) | FL, IL, MA, MI, NY, OH | View Drugs | |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | REGN4018 | anti-MUC16/CD3 bispecific antibody REGN4018 | Re-directs T cells to attack MUC16 (CA125)+ tumor cells | Clinical Trials | REGN5668 | | Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells | Clinical Trials |
|
|
| NCT04243499 | I/II | Recurrent ovarian cancer high levels of γ9δ2 T cells | A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer | CT | View Drugs | View Results |
ICT01 | | Activates gamma/delta T cells to stimulate immune response | Clinical Trials |
|
|
| NCT04761198 | I/II | Recurrent high grade serous or endometrioid ovarian cancer or advanced solid tumors with high TMB that are MS-Stable | A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE) | AZ, CA, FL, MA, MI, MN, NY, NC, OK, TN, TX, UT, VA | View Drugs | View Results |
Etigilimab | anti-TIGIT OMP-313M32, OMP-313M32 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable activation of DNAM-1 signaling in NK and CD8 T cells | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04907968 | I/II | Platinum sensitive ovarian cancer | An Open-label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin in Combination With Other Agent(s) In Participants With High-grade Serous Ovarian Cancer (UPGRADE) | AZ, MA, MI, OH, OR, PA, SC, UT, VA | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Upifitamab rilsodotin | XMT-1536, UpRi | ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA) | Clinical Trials |
|
|
| NCT04370587 | I/II | Advanced solid tumors with cutaneous or subcutaneous lesions - intratumoral injection (Phase II) | A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 When Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | AZ, MA, PA, TX | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | T3011 | oncolytic HSV-1-expressing IL-12 and anti-PD-1 antibody T3011 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT05262530 | I/II | Recurrent CLDN6+ ovarian cancer | First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors | TX, VA | View Drugs | |
BNT142 | BNT142 RiboMab (mRNA-encoded antibody) | Re-directs T cells to attack CLDN6+ tumor cells | Clinical Trials |
|
|
| NCT04528836 | I/Ib | Advanced solid tumors with KRAS G12C or NF1 loss of function mutations (in expansion) | A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors | CA, CO, TX, UT | View Drugs | |
BBP-398 | IACS-15509 | SHP2 inhibitor | Clinical Trials |
|
|
| NCT01434316 | I | Advanced solid tumors including those with BRCA1/2 mutations (in expansion) | Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors | MA | View Drugs | View Results |
Dinaciclib | CDK inhibitor SCH 727965, SCH 727965 | CDK1, 2, 5, 9 inhibitor | Clinical Trials | Veliparib | ABT-888 | PARP inhibitor | Clinical Trials |
|
|
| NCT02264678 | I | Platinum sensitive ovarian cancer that is BRCA MUT or with RAD51C/D MUT or HRD+ that must have progressed on PARP inhibitor therapy, no prior ATR inhibitor | A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies. | CA, MA, NY | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01543763 | I | Advanced solid tumors (in ovarian expansion) | Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | CA | View Drugs | View Results |
Abexinostat | PCI-24781, HDAC inhibitor CRA-024781 | HDAC inhibitor | Clinical Trials | Pazopanib | Votrient | Multi-targeted RTK inhibitor | |
|
|
| NCT01376505 | I | Advanced solid tumors (in ovarian expansion) | Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors | OH | View Drugs | View Results |
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine | B-Vaxx | Immune response against cancer expressing HER2 | Clinical Trials |
|
|
| NCT03023319 | I | Advanced solid tumors (in expansion) | Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | GA | View Drugs | View Results |
Bosutinib | SKI-606, Bosulif | Abl and src family kinase inhibitor | Approved in Other Cancers | Pemetrexed | Pemetrexed disodium, Alimta | DHFR and Thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT03054298 | I | Recurrent or persistent serous ovarian cancer | Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers | PA | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | huCART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials |
|
|
| NCT03386526 | I | Advanced solid tumors (in expansion) | A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies | MI, TX | View Drugs | View Results |
APG-1387 | | SMAC mimetic and IAP antagonist | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03059823 | I | Advanced solid tumors (in expansion) | A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors | TX | View Drugs | View Results |
Retifanlimab | MGA012, anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT03508570 | I | Recurrent ovarian cancer with disease in the peritoneal cavity or retroperitoneal lymph nodes (in ovarian expansion) | Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers | TX | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03585764 | I | Recurrent or persistent FRalpha+ high grade serous ovarian cancer | Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PA | View Drugs | |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | MOv19-BBz CAR T | | Immune response against cancer expressing folate receptor | Clinical Trials |
|
|
| NCT03530397 | I | Advanced solid tumors (in expansion) | A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors. | MI, NY, NC, RI, TN | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | MEDI5752 | anti-PD-1/CTLA-4 bispecific antibody MEDI5752 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pemetrexed | Pemetrexed disodium, Alimta | DHFR and Thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT03934814 | I | Advanced solid tumors (in ovarian expansion) | A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | AL, AZ, CT, FL, IN, MI, MN, NJ, NY, TN, WA | View Drugs | View Results |
Lemzoparlimab | TJC4, TJ011133 | Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03968406 | I | Recurrent ovarian cancer (amenable to radiation therapy) - without ascites | Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04053673 | I | Advanced solid tumors with TIPARP AMP (in expansion) | A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | CO, CT, FL, MA, PA, TN, TX | View Drugs | View Results |
RBN-2397 | | PARP7 inhibitor | Clinical Trials |
|
|
| NCT04149145 | I | Recurrent ovarian cancer that must have progressed on prior PARP inhibitor therapy (inc expansion) | Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer | AL | View Drugs | View Results |
|
|
| NCT04182516 | I | Advanced solid tumors (inc ovarian expansion) | A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors | TX | View Drugs | |
NMS-03305293 | | PARP inhibitor | Clinical Trials |
|
|
| NCT03454451 | I | Advanced solid tumors (in expansion) | A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination With Ciforadenant, With Pembrolizumab, and With Ciforadenant Plus Pembrolizumab in Adult Subjects With Advanced Cancers | AZ, CA, CT, FL, IL, MD, MA, NY, OH, OK, PA, SC, TN, VA | View Drugs | View Results |
Ciforadenant | adenosine-A2A receptor antagonist CPI-444, CPI-444 | Blocks adenosine A2a receptor inhibition of T cells | Clinical Trials | CPI-006 | anti-CD73 monoclonal antibody CPI-006, CPX-006 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04315233 | I | Recurrent serous ovarian cancer | A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE) | UT, VA | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04329494 | I | Recurrent ovarian cancer (with peritoneal disease) | Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) | CA, FL, NY | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | PIPAC | pressurized intraperitoneal aerosol chemotherapy | | Clinical Trials |
|
|
| NCT03954067 | I | Advanced solid tumors (in expansion) - intratumoral injection | A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced/Metastatic Solid Tumors | AL, AZ, CA, CT, IL, KY, LA, MD, MN, NE, NJ, NY, PA, SC, TX, VA | View Drugs | |
ASP9801 | oncolytic virus ASP9801 | Induces immune response and tumor cell lysis | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04526106 | I | Advanced solid tumors with FGFR2 alterations (in expansion) | A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors | AZ, CA, FL, IL, MA, MI, MN, NY, OH, PA, TX, UT | View Drugs | |
RLY-4008 | | FGFR2 inhibitor | Clinical Trials |
|
|
| NCT04608409 | I | Partially platinum sensitive, platinum resistant or refractory ovarian cancer | A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer | KY | View Drugs | |
Lapatinib | GW2016, GSK572016, lapatinib ditosylate, Tykerb | EGFR and HER2 kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04044859 | I | Advanced MAGE-A4+ solid tumors (in expansion) | A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Nivolumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | MA, MO, NY, NC, OK, PA, TN, TX, WI | View Drugs | View Results |
ADP-A2M4CD8 | SPEAR T-cell ADP-A2M4CD8, autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells | Immune response against cancer expressing MAGE-A4 | Clinical Trials |
|
|
| NCT04673448 | I | Recurrent BRCA MUT ovarian cancer | Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer | WA | View Drugs | View Results |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04669899 | I | Advanced solid tumors (inc ovarian expansion) | Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies | AL, AZ, CA, CT, DC, FL, GA, IL, KY, MI, MN, NY, NC, OH, OK, OR, SC, TX, UT, WA, WI | View Drugs | |
JTX-8064 | | Blocks ILT4 inhibition of immune cells | Clinical Trials | Pimivalimab | anti-PD-1 monoclonal antibody JTX-4014, JTX-4014 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT04703920 | I | Recurrent high grade serous ovarian cancer | A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | MI | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04707248 | I | Recurrent ovarian cancer (inc expansion) | Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | FL, OK, TN | View Drugs | |
DS-6000a | | ADC: anti-CDH6 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT04711161 | I | Recurrent ovarian cancer (inc expansion) | Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | TX | View Drugs | |
GRN-300 | | SIK2/3 inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04890613 | I | Ovarian cancer with germline BRCA2 or germline PALB2 alterations, or high grade serous or endometrioid ovarian cancer with BRCA1 alterations or other HRD-associated mutations | Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation | CA, MA, NY, PA | View Drugs | View Results |
Pidnarulex | Pol I inhibitor CX5461, RNA Pol I inhibitor CX5461, CX-5461 | Pol I inhibitor | Clinical Trials |
|
|
| NCT05057715 | I | Persistent or recurrent serous ovarian cancer | Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer | PA | View Drugs | View Results |
huCART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials | VCN-01 | PH20 hyaluronidase-expressing adenovirus VCN-01 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT05216432 | I | Advanced solid tumors with PIK3CA mutations (inc ovarian expansion) | A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | CO, FL, MA, TN, TX, VA | View Drugs | View Results |
RLY-2608 | | PI3K alpha inhibitor | Clinical Trials |
|
|
| NCT05229900 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors | MI | View Drugs | |
SGN-ALPV | | ADC: anti-ALPP + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT05238922 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | CA, CT, GA, NY, NC, PA | View Drugs | |
INCB123667 | | Undisclosed mechanism | Clinical Trials |
|
|
| NCT05300048 | I | Advanced solid tumors with PIK3CA MUT (inc ovarian expansion) | A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) in Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss | AL, CA, IL, MN, NY, NC, TX, WI | View Drugs | View Results |
Serabelisib | PI3K alpha inhibitor MLN1117, TAK-117, INK-1117, MLN1117 | PI3K alpha inhibitor | Clinical Trials |
|
|
| NCT03448042 | I | Advanced HER2+ solid tumors (in expansion) | A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers | NY, TN, TX | View Drugs | |
Runimotamab | BTRC 4017A, anti-HER2 x anti-CD3 bispecific monoclonal antibody BTRC 4017A | Re-directs T cells to attack HER2+ tumor cells | Clinical Trials | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers |
|
|
| NCT04847063 | I | Ovarian cancer with peritoneal disease - expected to undergo complete cytoreduction | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | MD | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | Floxuridine | WR-138720, 5-FUDR | RNA and DNA synthesis inhibitor | | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer | Mitomycin C | Ametycine, MITO-C, Mitocin, Mitolem, Mitosol, Mitozytrex, Mutamycin, NCI-C04706 | DNA synthesis inhibitor | Approved in Other Cancers | Oxaliplatin | OHP, Eloxatine, Dacplat, Dacotin, Eloxatin | DNA damaging agent | | Surgery | | | Clinical Trials |
|
|
| NCT05039801 | I | Advanced solid tumors with KEAP1, NF1, NFE2L2, or STK11 (LKB1) alterations, or platinum resistant or refractory high grade serous ovarian cancer with low expression of ASNS, or recurrent clear cell ovarian cancer with an ARID1A mutation (inc expansion) | A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors | TX | View Drugs | View Results |
IACS-6274 | glutaminase inhibitor IPN60090, IPN60090 | Glutaminase inhibitor | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05200364 | I | Recurrent high grade serous ovarian cancer (inc expansion) | A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) | PA, TN, VA | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | STRO-002 | | ADC: anti-FOLR1 + microtubule destabilizer (SC209) | Clinical Trials |
|
|